Iantrek: Leading the Way in Breakthrough Glaucoma Surgical Technologies
Iantrek Mission: to lead the way in biointerventional ophthalmic surgery
Founded in 2019, Iantrek, Inc. is a pioneering ophthalmic medical technology company born by Dr. Sean Ianchulev, MD, MPH, a renowned innovator in eye care and Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai. Established in White Plains, New York, with R&D Offices in Providence, Rhode Island, Iantrek focuses on developing micro- and bio-interventional solutions to advance the surgical treatment of chronic eye diseases, particularly glaucoma.
Founding Vision
Dr. Ianchulev's vision for Iantrek was to revolutionize glaucoma treatment by creating minimally invasive surgical options that enhance the eye's natural outflow pathways. Recognizing the limitations of existing treatments, he aimed to develop technologies that would provide safer and more effective solutions for patients suffering from this leading cause of irreversible blindness
Technological Innovations
Iantrek has developed several groundbreaking technologies:
CycloPen™ System: A micro-interventional device targeting the suprachoroidal outflow pathway, offering significant and sustained intraocular pressure (IOP) reduction.
AlloFlo™ Bio-Tissue Implant: A bio-interventional implant that provides a non-hardware-based treatment option for glaucoma surgery, enhancing uveoscleral outflow.
C-Rex™ Device: Designed for traditional goniotomy surgery, offering surgeons 360° circumferential and titratable excision of the trabecular meshwork.
These innovations position Iantrek as the only company with FDA-registered technologies designed to address both natural aqueous outflow pathways: trabecular and suprachoroidal.
Iantrek's technologies have demonstrated promising clinical outcomes. The CREST Registry study reported a 42% reduction in IOP from a medicated baseline of 22.6 mmHg to 13.2 mmHg at 12 months post-procedure. A 2-year prospective clinical study showed that 74% of treated eyes achieved a ≥20% reduction in IOP with the same or fewer glaucoma medications, and a mean IOP reduction of 34%.
Future Outlook
Iantrek plans to broaden the commercialization of its technologies in the U.S. market, with full commercial launches anticipated later this year. The company continues to develop additional bio-interventional and micro-interventional technologies targeting launches through 2026.For more information, visit www.iantrekmed.com.
